MX360816B - Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. - Google Patents
Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina.Info
- Publication number
- MX360816B MX360816B MX2015006336A MX2015006336A MX360816B MX 360816 B MX360816 B MX 360816B MX 2015006336 A MX2015006336 A MX 2015006336A MX 2015006336 A MX2015006336 A MX 2015006336A MX 360816 B MX360816 B MX 360816B
- Authority
- MX
- Mexico
- Prior art keywords
- insulin resistance
- improved peptide
- peptide pharmaceuticals
- pharmaceuticals
- modified peptides
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108091005601 modified peptides Proteins 0.000 abstract 2
- 108091005573 modified proteins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261728649P | 2012-11-20 | 2012-11-20 | |
| PCT/US2013/071077 WO2014081872A1 (en) | 2012-11-20 | 2013-11-20 | Improved peptide pharmaceuticals for insulin resistance |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015006336A MX2015006336A (es) | 2016-02-05 |
| MX360816B true MX360816B (es) | 2018-11-15 |
Family
ID=50776533
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015006336A MX360816B (es) | 2012-11-20 | 2013-11-20 | Productos farmacéuticos peptídicos mejorados para la resistencia a la insulina. |
| MX2018013981A MX2018013981A (es) | 2012-11-20 | 2015-05-20 | Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013981A MX2018013981A (es) | 2012-11-20 | 2015-05-20 | Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina. |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US11065304B2 (enExample) |
| EP (3) | EP2922876B1 (enExample) |
| JP (1) | JP6525456B2 (enExample) |
| KR (2) | KR102365582B1 (enExample) |
| CN (3) | CN104918961A (enExample) |
| AU (1) | AU2013347975B2 (enExample) |
| BR (1) | BR112015011478B1 (enExample) |
| CA (1) | CA2891931A1 (enExample) |
| DK (1) | DK2922876T3 (enExample) |
| MX (2) | MX360816B (enExample) |
| WO (1) | WO2014081872A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4286400A3 (en) | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| KR20230023059A (ko) * | 2011-05-18 | 2023-02-16 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| EP3444281B1 (en) * | 2012-11-20 | 2021-11-03 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| EP2934568B1 (en) | 2012-12-21 | 2017-10-18 | Sanofi | Dual glp1/gip or trigonal glp1/gip/glucagon agonists |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| CN106661097A (zh) | 2014-05-28 | 2017-05-10 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| EP3575314B1 (en) | 2014-12-30 | 2024-02-14 | Hanmi Pharm. Co., Ltd. | Glucagon derivative |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| MA49545B1 (fr) | 2015-06-30 | 2022-03-31 | Hanmi Pharm Ind Co Ltd | Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CN115920077B (zh) | 2015-12-31 | 2025-07-04 | 韩美药品株式会社 | 胰高血糖素/glp-1/gip受体三重激动剂的长效缀合物 |
| CA3029518A1 (en) * | 2016-06-29 | 2018-01-04 | Hanmi Pharm. Co., Ltd. | Glucagon derivative, conjugate thereof, composition comprising same, and therapeutic use thereof |
| EP3554531A1 (en) | 2017-01-24 | 2019-10-23 | MacRegen, Inc. | Treatment of age-related degeneration and other eye diseases with apolipoprotein mimetics |
| CA3054497A1 (en) | 2017-03-03 | 2018-09-07 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| HUE069178T2 (hu) | 2018-01-03 | 2025-02-28 | Mederis Diabetes Llc | Javított peptidgyógyszerek NASH és egyéb rendellenességek kezelésére |
| AU2021224246A1 (en) * | 2020-02-21 | 2022-09-15 | Spitfire Pharma Llc | GLP-1R and GCGR agonists, formulations, and methods of use |
| CN117202924A (zh) | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
| CN113461747B (zh) * | 2021-07-12 | 2023-02-03 | 吉林化工学院 | 刺玫果中2个具有降血糖活性的化合物 |
| CN119855586A (zh) * | 2022-07-29 | 2025-04-18 | 加利福尼亚大学董事会 | 用于治疗代谢障碍的组合物和方法 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
| US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
| AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5661130A (en) * | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
| JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
| US6720407B1 (en) * | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
| US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
| US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| EP2305313B1 (en) | 2001-10-10 | 2014-03-26 | ratiopharm GmbH | Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| WO2004093902A1 (en) | 2003-03-19 | 2004-11-04 | The General Hospital Corporation | CONFORMATIONALLY CONSTRAINED PARATHYROID HORMONES WITH α-HELIX STABILIZERS |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| EP1789075A4 (en) | 2004-08-25 | 2009-07-01 | Uab Research Foundation | ABSORPTION ENHANCER FOR DRUG ADMINISTRATION |
| US20110257096A1 (en) * | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
| ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
| WO2006096426A2 (en) | 2005-03-03 | 2006-09-14 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
| EP1883419A4 (en) | 2005-05-06 | 2010-08-04 | Bayer Pharmaceuticals Corp | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES |
| WO2007002465A2 (en) | 2005-06-23 | 2007-01-04 | Rapid Pharmaceuticals, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| EP1767545B1 (en) * | 2005-09-22 | 2009-11-11 | Biocompatibles UK Limited | GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance |
| WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
| US7998927B2 (en) * | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
| WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
| EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
| KR20090119876A (ko) | 2007-02-15 | 2009-11-20 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 글루카곤/ｇｌｐ-1 수용체 공동-항진물질 |
| WO2009155258A2 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| ME02220B (me) | 2009-07-13 | 2016-02-20 | Zealand Pharma As | Analozi acilovanog glukagona |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| CN102892425A (zh) * | 2010-01-20 | 2013-01-23 | 西兰制药公司 | 心脏病症的治疗 |
| EP2552951A1 (en) * | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| AU2011349331A1 (en) * | 2010-12-22 | 2013-07-11 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting GIP receptor activity |
| KR101453037B1 (ko) | 2011-03-23 | 2014-10-21 | 주식회사 엘지화학 | 전극조립체 및 이의 제조방법 |
| EP4286400A3 (en) | 2011-05-18 | 2024-06-05 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| KR20230023059A (ko) | 2011-05-18 | 2023-02-16 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 제약 |
| JP2014011554A (ja) * | 2012-06-28 | 2014-01-20 | Seiichi Onoda | 光線路監視方法、および光線路監視システム |
| EP3444281B1 (en) | 2012-11-20 | 2021-11-03 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
| CN104918961A (zh) | 2012-11-20 | 2015-09-16 | 梅德瑞斯糖尿病有限责任公司 | 用于胰岛素抗性的改良的肽药物 |
| CN106661097A (zh) * | 2014-05-28 | 2017-05-10 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
| HUE069178T2 (hu) * | 2018-01-03 | 2025-02-28 | Mederis Diabetes Llc | Javított peptidgyógyszerek NASH és egyéb rendellenességek kezelésére |
| AU2021224246A1 (en) * | 2020-02-21 | 2022-09-15 | Spitfire Pharma Llc | GLP-1R and GCGR agonists, formulations, and methods of use |
-
2013
- 2013-11-20 CN CN201380069707.1A patent/CN104918961A/zh active Pending
- 2013-11-20 JP JP2015543145A patent/JP6525456B2/ja active Active
- 2013-11-20 US US14/646,264 patent/US11065304B2/en active Active
- 2013-11-20 KR KR1020217003371A patent/KR102365582B1/ko active Active
- 2013-11-20 BR BR112015011478-4A patent/BR112015011478B1/pt active IP Right Grant
- 2013-11-20 EP EP13856357.2A patent/EP2922876B1/en active Active
- 2013-11-20 MX MX2015006336A patent/MX360816B/es active IP Right Grant
- 2013-11-20 WO PCT/US2013/071077 patent/WO2014081872A1/en not_active Ceased
- 2013-11-20 CN CN202311534812.XA patent/CN117903257A/zh active Pending
- 2013-11-20 EP EP18193667.5A patent/EP3434696A1/en not_active Withdrawn
- 2013-11-20 CN CN202410444323.3A patent/CN118324870A/zh active Pending
- 2013-11-20 AU AU2013347975A patent/AU2013347975B2/en active Active
- 2013-11-20 CA CA2891931A patent/CA2891931A1/en active Pending
- 2013-11-20 EP EP19188938.5A patent/EP3653649A1/en active Pending
- 2013-11-20 KR KR1020157016555A patent/KR102213907B1/ko active Active
- 2013-11-20 DK DK13856357.2T patent/DK2922876T3/en active
-
2015
- 2015-05-20 MX MX2018013981A patent/MX2018013981A/es unknown
-
2021
- 2021-06-16 US US17/349,195 patent/US11911447B2/en active Active
-
2024
- 2024-02-26 US US18/587,927 patent/US20240424062A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3653649A1 (en) | 2020-05-20 |
| US11911447B2 (en) | 2024-02-27 |
| BR112015011478A2 (enExample) | 2017-08-15 |
| MX2015006336A (es) | 2016-02-05 |
| CN118324870A (zh) | 2024-07-12 |
| WO2014081872A1 (en) | 2014-05-30 |
| CN104918961A (zh) | 2015-09-16 |
| US20240424062A1 (en) | 2024-12-26 |
| AU2013347975A1 (en) | 2015-06-11 |
| EP3434696A1 (en) | 2019-01-30 |
| EP2922876A1 (en) | 2015-09-30 |
| EP2922876B1 (en) | 2018-10-10 |
| KR20210016083A (ko) | 2021-02-10 |
| US20220362345A1 (en) | 2022-11-17 |
| MX2018013981A (es) | 2021-11-16 |
| BR112015011478B1 (pt) | 2022-10-25 |
| AU2013347975B2 (en) | 2018-07-26 |
| US20150290334A1 (en) | 2015-10-15 |
| DK2922876T3 (en) | 2019-02-04 |
| KR102365582B1 (ko) | 2022-02-18 |
| EP2922876A4 (en) | 2016-06-01 |
| KR102213907B1 (ko) | 2021-02-09 |
| KR20150088294A (ko) | 2015-07-31 |
| JP2016501204A (ja) | 2016-01-18 |
| US11065304B2 (en) | 2021-07-20 |
| CA2891931A1 (en) | 2014-05-30 |
| JP6525456B2 (ja) | 2019-06-05 |
| CN117903257A (zh) | 2024-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018013981A (es) | Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina. | |
| MX344219B (es) | Productos farmaceuticos peptidicos mejorados para resistencia a insulina. | |
| WO2012158964A3 (en) | Improved peptide pharmaceuticals for osteoporosis | |
| MX384236B (es) | Productos farmaceuticos mejorados de peptido para resistencia a la insulina | |
| AU2019201173B2 (en) | Novel polypeptides | |
| SG11201403450VA (en) | Artificial nucleic acid molecules for improved protein or peptide expression | |
| WO2013184939A3 (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
| TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
| WO2015037000A8 (en) | Vstm5 polypeptides and uses thereof for treatment of cancer, infectious diseases and immune related diseases | |
| EP2935338A4 (en) | Fusion protein of therapeutic polypeptide with improved pharmacokinetic profile and use thereof | |
| BR112014022788A2 (pt) | peptídeo, polipeptídeos, ácido nucleico, composição farmacêutica, conjugado e método in vitro | |
| WO2013152351A3 (en) | Fusion polypeptides and methods of use thereof | |
| IN2015DN02349A (enExample) | ||
| WO2014100481A8 (en) | Modified alpha hemolysin polypeptides and methods of use | |
| MY166157A (en) | Antibodies to bradykinin b1 receptor ligands | |
| EP3013789A4 (en) | Amino acid and peptide conjugates and conjugation process | |
| EP3024472A4 (en) | Ophthalmic uses of toxin-based therapeutic peptides and pharmaceutical compositions thereof | |
| MX2014004953A (es) | Ligadores basados en tirosina para la conexion desprendible de peptidos. | |
| SG179200A1 (en) | Fusion polypeptides and uses thereof | |
| IL227737A0 (en) | A substance for drug delivery capable of passing through the blood-brain barrier, and a peptide and its use | |
| EP3237374A4 (en) | Amino acid and peptide conjugates and uses thereof | |
| WO2015057820A3 (en) | Peptide constructs and well-defined aggregates thereof | |
| WO2014039074A3 (en) | Therapeutic compositions and related methods | |
| IN2014CN00510A (enExample) | ||
| EP3319613A4 (en) | Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |